Author(s)
Pouls B1, Kristensen LE2, Petersson M3, van den Bemt BJ4, van Bracht E5, Bruggraber R6, Mountian I7, Wiegratz S8, Karlen H9, Ballerini L10, Jørgensen TS2
1Sint Maartensliniek and Radboud University Medical Center, Ubbergen, GE, Netherlands, 2The Parker Institute, Copenhagen, Denmark, 3Linkoping University, Sweden, Sweden, 4Sint Maartensliniek and Radboud University Medical Center, Nijmegen, Netherlands, 5UCB Pharma, Breda, Netherlands, 6UCB Pharma, Slough, UK, 7UCB Pharma, Brussels, Belgium, 8UCB Pharma, Monheim am Rhein, Germany, 9UCB Pharma, Stockholm, Sweden, 10UCB Pharma, Bulle, Switzerland
OBJECTIVES ava®, a new electromechanical injection device (e-Device) for self-injecting certolizumab pegol (CZP) has been developed with the aim of improving self-injection experience.1 The objective of this study was to assess patient experience of self-injection with the e-Device and determine patient device preference. METHODS Patients aged 18–85 years self-injecting CZP using a pre-filled syringe (PFS) or pre-filled pen (PFP) were recruited from the Netherlands, Denmark and Sweden. Patients completed a pre-injection assessment of self-injection (ASI) questionnaire evaluating patient self-injection perception. Following e-Device training, patients carried out three CZP injections, each two weeks apart. After each injection, patients completed a post-injection ASI questionnaire evaluating their experience. Post-ASI questions were clustered into six domains: feelings about self-injection, self-image, self-confidence, ease of use, satisfaction, and adverse reactions. Following the third injection, patients completed a preference questionnaire assessing their self-injection device preference. RESULTS Fifty-nine patients participated (Netherlands: 24; Denmark: 15; Sweden: 20). Patients from Sweden did not respond to all questions, therefore only preference questionnaire results are reported from Sweden. In the pre-ASI, 4/39 (10.3%) patients stated they were ‘very’ or ‘extremely’ afraid of injections, and 33/39 (84.6%) felt ‘very’ or ‘extremely’ confident self-injecting correctly with their current device. Overall, patients scored the e-Device favourably across all post-ASI domains following each injection. Across all countries, 56/59 patients answered the preference questionnaire; 32/56 (57.1%) patients chose the e-Device, 15/56 (26.8%) preferred the PFS or PFP, 9/56 (16.1%) had no preference. CONCLUSIONS Patients were satisfied with the e-Device preferring it to their previous devices; this suggests it may address current unmet patient needs. Including the e-Device as part of a portfolio of self-injection device options may improve patient experience. REFERENCES 1. Domanska B. Adv Ther 2018;35:100–15.
Conference/Value in Health Info
2019-11, ISPOR Europe 2019, Copenhagen, Denmark
Code
PMD60
Topic
Medical Technologies, Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance, Medical Devices, Patient Engagement, Stated Preference & Patient Satisfaction
Disease
Biologics and Biosimilars, Medical Devices, Multiple Diseases